The grape fruit flavonone naringin protects mice against doxorubicin-induced cardiotoxicity

Ganesh Chandra Jagetia, Tiyagura Koti Reddy


Doxorubicin (DOX), an anthracycline drug widely used for the treatment of various cancers, causes a cumulative dose-dependent cardiac toxicity that is characterized by an irreversible cardiomyopathy and congestive heart failure. The cardioprotective effect of 2.5, 5, 7.5 and 10 mg/kg naringin (NIN) was studied in mice treated with 15 mg/kg DOX. The animals were killed 30 h after DOX treatment. The latter induced acute cardiotoxicity indicated by a significant elevation in glutamic pyruvic transaminase (GPT), glutamic oxaloacetic transaminase (GOT), creatine kinase (CK-MB) and lactate dehydrogenase (LDH) in mice serum. Treatment of mice with NIN before DOX administration significantly reduced serum levels of GPT, GOT, CK-MB and LDH indicating that NIN protected against the DOX-induced cardiotoxicity. DOX induced a significant increase in the 8-OHdG DNA adducts and the PARP activity in the heart and liver of mice, whereas NIN treatment of mice before DOX administration significantly reduced 8-OHdG DNA adducts and PARP activity in the heart and liver. Similarly, NIN inhibited the DOX-induced decline in the glutathione concentration, catalase and superoxide dismutase activities and abated DOX-induced lipid peroxidation in the heart and liver of mice. Intraperitoneal administration of 1.25 mg/kg DOX significantly elevated survival of Ehrlich ascites carcinoma (EAC) bearing mice, whereas the combination of 10 mg/kg NIN with DOX did not alter the tumor cell growth, median survival time or average survival time of tumor bearing mice when compared to DOX treatment alone, indicating that NIN does not interfere with the antineoplastic activity of DOX. Our study demonstrates that naringin reduced the doxorubicin-induced cardiotoxicity, without affecting its antineoplastic activity, which may be due to reduction in the DOX-induced 8-OHdG DNA adducts and PARP activity, increase in the antioxidant enzymes and alleviation of lipid peroxidation by naringin.


Doxorubicin; mice; cardiotoxicity; glutathione; PARP; DNA adducts


Abd El-Aziz MAAI, Othman MA & El-Missiry MA 2001 Potential protective role of angiotension-converting enzyme inhibitors captopril and enalapril against adriamycin-induced acute cardiac and hepatic toxicity in rats. J Applied Toxicol 21 469-473

Abei H 1984 Catalase in vitro. Methods Enzymol 105 121-126

Agarwal OP & Nagaratnam A 1981 Radioprotective property of flavonoids in mice. Toxicon 19 201-204

Ali M, Kamjoo M, Thomas HD, Kyle S, Pavlovska I, Babur M, Telfer BA, Curtin NJ & Williams KJ 2011 The clinically active PARP inhibitor AG014699 ameliorates cardiotoxicity but does not enhance the efficacy of doxorubicin, despite improving tumor perfusion and radiation response in mice. Mol Cancer Ther 10 2320-2329

Arafa H, Abd-Ellah MF & Hafez HF 2005 Abatement by Naringenin of Doxorubicin-Induced Cardiac toxicity in Rats. J Egypt Nat Cancer Inst 17 291-300

Asensio-Lopez MC, Sanchez-Mas J, Pascual-Figal DA, de Torre C, Valdes M & Lax A 2013 Ferritin heavy chain as main mediator of preventive effect of metformin against mitochondrial damage induced bydoxorubicin in cardiomyocytes. Free Radic Biol Med 67C 19-29

Bachur NR, Gordon SL & Gee MV 1978 A general mechanism for microsomal activation of quinone anticancer agents to free radicals. Cancer Res 38 1745-1750

Broggini M & D'Incalci M 1994 Modulation of transcription factor-DNA interactions by anticancer drugs. Anticancer Drug Des 9 373-387

Burkart V, Wang ZQ, Radons J, Heller B, Herceg Z, Stingl L, Wagner EF & Kolb H 1999 Mice lacking the poly(ADP-ribose) polymerase gene are resistant to pancreatic beta-cell destruction and diabetes development induced by streptozocin. Nat Med 5 314-319

Camargo CA, Gomes-Marcondes MC, Wutzki NC & Aoyama H 2012 Naringin inhibits tumor growth and reduces interleukin-6 and tumor necrosis factor α levels in rats with Walker 256 carcinosarcoma. Anticancer Res 32 129-133

Carter SK 1975 Adriamycin - A review. J Nat Cancer Inst 55 1265-1274

Coldwell KE, Ognibene SM, Ognibene TJ, Henderson PT and Phillips DR 2008 Detection of Adriamycin–DNA adducts by accelerator mass spectrometry at clinically relevant Adriamycin concentrations. Nucleic Acids Res 36 e100

Cullinane C & Phillips DR 1990 Induction of stable transcriptional blockage sites by adriamycin: GpC specificity of apparent adriamycin-DNA adducts and dependence on iron(III) ions. Biochemistry 29 5638-5646

Curtin NJ & Szabo C 2013 Therapeutic applications of PARP inhibitors: anticancer therapy and beyond. Mol Aspects Med 34 1217-1256

Cutts SM, Parsons PG, Sturm RA & Phillips DR 1996 Adriamycin-induced DNA adducts inhibit the DNA interactions of transcription factors and RNA polymerase. J Biol Chem 271 5422-5429

DeAtley SM, Aksenov MY, Aksenova MV, Harris B, Hadley R, Cole Harper P, Carney JM & Butterfield DA 1999 Anti-oxidants protect against reactive oxygen species associated with Doxorubicin-treated cardiomyocytes. Cancer Lett 136 41-46

Devanaboyina U & Gupta RC 1996 Sensitive detection of 8-hydroxy-2'deoxyguanosine in DNA by 32P-postlabeling assay and the basal levels in rat tissues. Carcinogenesis 17 917-924

Do K & Chen AP 2013 Molecular pathways: targeting PARP in cancer treatment. Clin Cancer Res 19 977-984

Doroshow JH, Synold TW, Somlo G, Akman SA & Gajewski E 2001 Oxidative DNA base modifications in peripheral blood mononuclear cells of patients treated with high-dose infusional doxorubicin. Blood 97 2839-2845

Eliasson MJ, Sampei K, Mandir AS, Hurn PD, Traystman RJ, Bao J, Pieper A, Wang ZQ, Dawson TM, Snyder SH & Dawso VL 1997 Poly (ADP-ribose) polymerase gene disruption renders mice resistant to cerebral ischemia. Nat Med 3 1089-1095

Gelvan D & Saltman P 1990 Different cellular targets of Cu- and Fe-catalyzed oxidation observed using a Cu-compatible thiobarbiturate acid assay. Biochimica Biophysica Acta 1035 353-360

Gewirtz DA 1999 A critical evaluation of the mechanisms of action proposed for the antitumor effects of the anthracycline antibiotics Doxorubicin and daunorubicin. Biochem Pharmacol 57 727-741

Goebel M & Kaplan E 1992 Anthracycline-induced cardiotoxicity: a review. Onkologie 15 198-204

Goldspink PH, Thomason DB & Russell B 1996 Beating affects the posttranscriptional regulation of alpha-myosin mRNA in cardiac cultures. Am J Physiol 271 H2584-2590

Guirouilh-Barbat J, Redon C & Pommier Y 2008 Transcription-coupled DNA double-strand breaks are mediated via the nucleotide excision repair and the Mre11-Rad50-Nbs1 complex. Mol Biol Cell 9 3969-3981

Guo RM, Xu WM, Lin JC, Mo LQ, Hua XX, Chen PX, Wu K, Zheng DD & Feng JQ 2013 Activation of the p38 MAPK/NF-κB pathway contributes to doxorubicin-induced inflammation and cytotoxicity in H9c2 cardiac cells. Mol Med Rep 8 603-608

Halliwell B & Gutteridge JMC 1989 Free Radicals in Biology and Medicine. Edn 2. New York: Oxford University Press

Horacek JM, Pudil R, Tichy M,J ebavy L, Zak P, Slovacek L & Maly J 2007 Biochemical markers and assessment of cardiotoxicity during preparative regimen and hematopoietic cell transplantation in acute leukemia. Exp Oncol 29 243-247

Jagetia GC & Reddy TK 2002 The grapefruit flavanone naringin protects against the radiation-induced genomic instability in the mice bone marrow: a micronucleus study. Mutat Res 26 37-48

Jagetia GC & Reddy TK 2004 Chemopreventive effect of naringin on the benzo (a) pyrene-induced forestomach carcinoma in mice. Int J of Cancer Prevent 6 429-444

Jagetia GC & Reddy TK 2011 Alleviation of iron induced oxidative stress by the grape fruit flavanone naringin in vitro. Chem Biol Interact 190 121-128

Jagetia GC, Venkatesha VA & Reddy TK 2003 Naringin, a citrus flavonone, protects against radiation-induced chromosome damage in mouse bone marrow. Mutagenesis 18 337-343

Jagetia GC & Reddy TK 2005 Modulation of radiation induced alteration in the antioxidant status of mice by naringin. Life Sci 77 780-794

Jagetia GC, Reddy TK, Malagi KJ, Nayak BS, Naidu MB, Ravikiran PB, Kamath SU, Shetty PC & Reddy DS 2005 Antarth, a polyherbal preparation protects against the doxorubicin-induced toxicity without compromising its antineoplastic activity. Phytother Res 19 772-778

Jagetia GC, Reddy TK, Venkatesha VA & Kedlaya R 2004 Influence of naringin on ferric iron induced oxidative damage in vitro. Clin Chim Acta 347 189-197

Jagetia GC, Reddy TK, Venkatesha VA & Kedlaya R 2004 Influence of naringin on ferric iron induced oxidative damage in vitro. Clin Chim Acta 347 189-197

Jeon SM, Bok SH, Jang MK, Lee MK, Nam KT, Park YB, Rhee SJ & Choi MS 2001 Antioxidative activity of naringin and lovastatin in high cholesterol-fed rabbits. Life Sci 69 2855-2866

Kaiserová H, Simůnek T, van der Vijgh WJ, Bast A & Kvasnicková E 2007 Flavonoids as protectors against doxorubicin cardiotoxicity: role of iron chelation, antioxidant activity and inhibition of carbonyl reductase. Biochim Biophys Acta 17721065-1074

Kalyanaraman B, Joseph J, Kalivendi S, Wang S, Konorev E & Kotamraju S 2002 Doxorubicin-induced apoptosis: implications in cardiotoxicity. Mol Cell Biochem 234 119-124

Kasai H & Nishimura S 1983 Hydroxylation of the C-8 position of deoxyguanosine by reducing agents in the presence of oxygen. Nucleic Acids Symp Ser 12 165-167

Klaunig JE, Goldblatt PJ, Hinton DE, Lipsky MM, Chacko J & Trump BF 1981 Mouse liver cell culture. I. Hepatocyte isolation. In Vitro 17 913-925

Li D, Li J, An Y, Yang Y & Zhang SQ 2013 Doxorubicin-induced apoptosis in H9c2 cardiomyocytes by NF-κB dependent PUMA upregulation. Eur Rev Med Pharmacol Sci 17 2323-2329

Liaudet L, Soriano FG, Szabo E, Virag L, Mabley JG, Salzman AL & Szabo C 2000 Protection against hemorrhagic shock in mice genetically deficient in poly(ADP-ribose)polymerase. Proc Natl Acad Sci 97 10203-10208

Lim SC 2013 Interrelation between expression of ADAM 10 and MMP 9 and synthesis of peroxynitrite in doxorubicin induced cardiomyopathy. Biomol Ther 21 371-380

Luo X & Kraus WL 2012 On PAR with PARP: cellular stress signaling through poly(ADP-ribose) and PARP-1. Genes Dev 26 417-432

Magan N, Isaacs RJ & Stowell KM 2012 Treatment with the PARP-inhibitor PJ34 causes enhanced doxorubicin-mediated cell death in HeLa cells. Anticancer Drugs 23 627-637

Marklund S & Marklund G 1974 Involvement of the superoxide anion radical in the autooxidation of pyrogallol and a convenient assay for superoxide dismutase. Eur J Biochem 47 469-474

Martin WM & McNally NJ 1980 Cytotoxicity of adriamycin to tumour cells in vivo and in vitro. Br J Cancer 42 881-889

Mimić-Oka J, Simić DV & Simić TP 1999 Free radicals in cardiovascular diseases. Med Biology 6 11-22

Minotti G, Recalcati S, Menna P, Salvatorelli E, Corna G & Cairo G 2004 Doxorubicin cardiotoxicity and the control of iron metabolism: quinone-dependent and independent mechanisms. Methods Enzymol 378 340-361

Miyake T & Shibamoto T 1996 Simultaneous determination of acrolein, malonaldehyde and 4-hydroxy-2-nonenal produced from lipids oxidized with Fenton's reagent. Food Chem Toxicol 34 1009-1011

Mizutani H, Oikawa S, Hiraku Y, Murata M, Kojima M & Kawanishi S 2003 Distinct mechanisms of site-specific oxidative DNA damage by doxorubicin in the presence of copper(II) and NADPH-cytochrome P450 reductase. Cancer Sci 94 686-691

Montaigne D, Hurt C & Neviere R 2012 Mitochondria death/survival signaling pathways in cardiotoxicity induced by anthracyclines and anticancer-targeted therapies. Biochem Res Int 951539

Moron MS, Depierre JW & Mannervik B 1979 Levels of glutathione, glutathione reductase and glutathione S-transferase activities in rat lung and liver. Biochima Biophys Acta 582 67-78

Myers C 1998 The role of iron in doxorubicin-induced cardiomyopathy. Semin Oncol 25 10-14

Olson RD & Mushlin PS 1990 Doxorubicin cardiotoxicity: analysis of prevailing hypotheses. FASEB J 4 3076-3086

Orsolya S, Péter Kemecsei, Max FJ, Holthuijsen Natal AW, Van Riel, Ger J vander Vusse, Pál Pacher, Szabó C, Márk K, László Ligeti & Tamás Ivanics 2005 Poly (ADP-ribose) polymerase regulates myocardial calcium handling in doxorubicin -induced heart failure Biochem Pharmacol 69 725-732

Pacher P & Szabo C 2007 Role of Poly(ADP-ribose) polymerase 1 (PARP-1) in Cardiovascular Diseases: The Therapeutic Potential of PARP Inhibitors. Cardiovasc Drug Rev 25 235-260

Pacher P & Szabo C 2008 Role of the peroxynitrite-poly(ADP-ribose)polymerase pathway in human disease. Am J Pathol 173 2-13

Pacher P, Liaudet L, Bai P, Virag L, Mabley JG & Hasko G 2002 Activation of poly (ADP-ribose) polymerase contributes to development of doxorubicin-induced heart failure. J Pharmacol Exp Ther 300 862-867

Pacher P, Liaudet L, Mabley JG, Cziraki A, Hasko G & Szabo C 2006 Beneficial effects of a novel ultrapotent poly(ADP-ribose) polymerase inhibitor in murine models of heart failure. Int J Mol Med 17 369-375

Pointon AV, Walker TM, Phillips KM, Luo J, Riley J, Zhang SD, Parry JD, Lyon JJ, Marczylo EL & Gant TW 2010 Doxorubicin in vivo rapidly alters expression and translation of myocardial electron transport chain genes, leads to ATP loss and caspase 3 activation. PLoS One 5 e12733

Poirier MC, Santella RM & Weston A 2000 Carcinogen macromolecular adducts and their measurement. Carcinogenesis 21 353-359

Powis G 1989 Free radical formation by antitumor quinones. Free Radical Biol Med 6 63-101

Reitman S & Frankel SA 1957 Colorimetric method for determination of serum glutamic oxaloacetic and glutamic pyruvic transaminase. Am J Clin Pathol 28 56-60

Satoh M, Naganuma A & Imura N 2000 Modulation of adriamycin toxicity by tissue-specific induction of metallothionein synthesis in mice. Life Sci 67 627-634

Sepe DM, Ginsberg JP & Balis FM 2010 Dexrazoxane as a cardioprotectant in children receiving anthracyclines. Oncologist 15 1220-1226

Serrano J, Palmeira CM, Kuehl DW & Wallace KB 1999 Cardioselective and cumulative oxidation of mitochondrial DNA following subchronic doxorubicin administration. Biochim Biophys Acta 1411 201-215

Singal PK, Iliskovic N, Li T & Kumar D 1997 Adriamycin cardiomyopathy: pathophysiology and prevention. FASEB J 11 931-936

So FV, Guthrie N, Chambers AF, Moussa M & Carroll KK 1996 Inhibition of human breast cancer cell proliferation and delay of mammary tumorigenesis by flavonoids and citrus juices. Nutr Cancer 26 167-181

Soriano FG, Pacher P, Mabley J, Liaudet L & Szabo C 2001a Rapid reversal of the diabetic endothelial dysfunction by pharmacological inhibition of poly (ADP-ribose) polymerase. Circulation Res 89 684-691

Soriano FG, Virag L & Szabo C 2001b Diabetic endothelial dysfunction: role of reactive oxygen and nitrogen species production and poly(ADP-ribose) polymerase activation. J Mol Med 79 437-448

Swift LP, Rephaeli A, Nudelman A, Phillips DR & Cutts SM 2006 Doxorubicin-DNA adducts induce a non-topoisomerase II-mediated form of cell death. Cancer Res 66 4863-4871

Szabo G, Liaudet L, Hagl S & Szabo C 2004 Poly (ADP-ribose) polymerase activation in the reperfused myocardium. Cardiovasc Res 61 471-480

Szabo G, Soos P, Heger U, Flechtenmacher C, Bahrle S, Zsengeller Z, Szabo C & Hagl S 2005 Poly (ADP-ribose) polymerase inhibition attenuates biventricular reperfusion injury after orthotopic heart transplantation. Eur J Cardiothorac Surg 27 226-234

Szántó M, Rutkai I, Hegedus C, Czikora Á, Rózsahegyi M, Kiss B, Virág L, Gergely P, Tóth A & Bai P 2011 Poly(ADP-ribose) polymerase-2 depletion reduces doxorubicin-induced damage through SIRT1 induction. Cardiovasc Res 92 430-438

Szenczi O, Kemecsei P, Holthuijsen MF, Van Riel NA, Vander Vusse GJ, Pacher P, Szabo C, Kollai M, Ligeti L & Ivanics T 2005 Poly (ADP-ribose) polymerase regulates myocardial calcium handling in doxorubicin-induced heart failure. Biochem Pharmacol 69 725-732

Tacar O, Sriamornsak P & Dass CR 2013 Doxorubicin: an update on anticancer molecular action, toxicity and novel drug delivery systems. J Pharm Pharmacol 65 157-170

Tatlidede E, Sehirli O, Velioğlu-Oğünc A, Cetinel S, Yeğen BC, Yarat A, Süleymanoğlu S & Sener G 2009 Resveratrol treatment protects against doxorubicin-induced cardiotoxicity by alleviating oxidative damage. Free Radic Res 43 195-205

Tikoo K, Sane MS & Gupta C 2011 Tannic acid ameliorates doxorubicin-induced cardiotoxicity and potentiates its anti-cancer activity: potential role of tannins in cancer chemotherapy. Toxicol Appl Pharmacol 251 191-200

Valavanidis A, Vlachogianni T & Fiotakis C 2009 8-hydroxy-2' -deoxyguanosine (8-OHdG): A critical biomarker of oxidative stress and carcinogenesis. J Environ Sci Health C Environ Carcinog Ecotoxicol Rev 27 120-139

Valls-Belles V, Torres Mdel C, Boix L, Muñiz P, Gonzalez-Sanjose ML & Codoñer-Franch P 2008 α-Tocopherol, MDA–HNE and 8-OHdG levels in liver and heart mitochondria of adriamycin-treated rats fed with alcohol-free beer. Toxicology 249 97-101

van Acker FA, Boven E, Kramer K, Haenen GR, Bast A & van der Vijgh WJ 2001 Frederine, a new and promising protector against doxorubicin-induced cardiotoxicity. Clin Cancer Res 7 1378-1384

Van der Vliet, PC & Verrijzer CP 1993 Bending of DNA by transcription factors. Bioessays 15 25-32

Venkatesan N 1998 Curcumin attenuation of acute adriamycin myocardial toxicity in rats. Br J Pharmacol 124 425-427

Vrtis KB, Markiewicz RP, Romano LJ & Rueda D 2013 Carcinogenic adducts induce distinct DNA polymerase binding orientations. Nucleic Acids Res 41 7843-7853

Wallace KB 2007 Adriamycin-induced interference with cardiac mitochondrial calcium homeostasis. Cardiovasc Toxicol 7 101-107

Weiss RB 1992 The anthracyclines: will we ever find a better doxorubicin? Semin Oncol 19 670-686

Wu LL, Chiou CC, Chang PY & Wu JT 2004 Urinary 8-OHdG: a marker of oxidative stress to DNA and a risk factor for cancer, atherosclerosis and diabetics. Clin Chim Acta 339 1-9

Zhou S, Palmeira CM & Wallace KB 2001 Doxorubicin-induced persistent oxidative stress to cardiac myocytes. Toxicol Lett 121 151-157

Zingarelli B, Salzman AL & Szabo C 1998 Genetic disruption of poly (ADP-ribose) synthetase inhibits the expression of P-selectin and intercellular adhesion molecule-1 in myocardial ischemia/reperfusion injury. Circulation Res 83 85-94

Full Text: PDF


  • There are currently no refbacks.

Copyright © 2017 Lorem Ipsum Press